

Remarks

By this Amendment, claims 1-7 have been amended; claims 8 and 9 have been canceled and new claims 10-14 have been added.

No new matter has been added by these amendments.

The Commissioner is hereby authorized to charge any fees under 37 CFR 1.16 or 1.17 as required by this paper to Deposit Account 19-0065.

Respectfully Submitted



David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.: 352-375-8100

Address: Saliwanchik, Lloyd & Saliwanchik
2421 N.W. 41st Street
Suite A-1 Gainesville, FL 32606

DRS/la

Attachment: Marked-up Version of Amended claims
Abstract (page 9)

BEST AVAILABLE COPY

Marked-up Version of Amended ClaimsClaim 1 (amended):

[Use] A method for treating a sensory, motor and/or cognitive deficit wherein said method comprises the intracerebral administration of a haemapoietic stem cell to a patient in need of such treatment [of a haematopoietic stem cell in the manufacture of a medicament for the treatment of a sensory, motor and/or cognitive deficit].

Claim 2 (amended):

[Use] The method, according to claim 1, which comprises [for] intracerebral transplantation of said stem cell into a damaged brain.

Claim 3 (amended):

[Use] The method, according to claim 1[or claim 2], wherein the treatment is for a condition selected from the group consisting of Alzheimer's disease, Parkinson's disease, Korsakoff's disease [or] and Creuzfeld-Jacob disease.

Claim 4 (amended):

[Use] The method, according to [any preceding claim] claim 1, wherein [the] said haematopoietic stem cell is conditionally immortal.

Claim 5 (amended):

[Use] The method, according to claim 4, wherein [the] said cell comprises a temperature sensitive oncogene which is not expressed at a temperature above 35 C.

Claim 6 (amended):

[Use] The method, according to claim 5, wherein [the] said oncogene expresses the SV40 T- antigen.

Claim 7 (amended):

[Use] The method, according to [any preceding claim] claim 1, wherein [the] said haematopoietic stem cell is genetically transformed to express a therapeutic heterologous gene product.

PCT/US2003/035009

BEST AVAILABLE COPY